Want to see ADGM full AI Analyst Report?
Top Page
Adagio Medical Holdings
(NASDAQ:ADGM)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.74
▲(53.54% Upside)
Action:Reiterated
Date:08/11/26
The score is held down primarily by weak financial performance (no revenue, persistent losses and cash burn, and slightly negative equity with rising debt). Technicals provide some near-term support (price above 20/50-day averages with positive MACD), but longer-term trend remains weak (below 100/200-day). Corporate events are a net mixed contributor, balancing a meaningful FDA PMA milestone against Nasdaq bid-price compliance risk, while valuation is constrained by negative earnings and no dividend.
Positive Factors
Regulatory progress: PMA filed
Filing a PMA is a structural milestone that moves the company from investigational status toward a formal FDA approval pathway. With Breakthrough Device designation and a PMA in place, the product gains a defined regulatory route that can unlock commercialization, reimbursement, and durable revenue opportunities if approved.
Negative Factors
No commercial revenue
The company has not yet converted clinical or regulatory progress into sales; zero recent revenue means the business remains pre‑commercial. Long‑term sustainability depends on successfully launching, scaling sales, and securing reimbursement—each a material execution hurdle that must be cleared to reach self‑sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress: PMA filed
Filing a PMA is a structural milestone that moves the company from investigational status toward a formal FDA approval pathway. With Breakthrough Device designation and a PMA in place, the product gains a defined regulatory route that can unlock commercialization, reimbursement, and durable revenue opportunities if approved.
Read all positive factors
Adagio Medical Holdings (ADGM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.18M
Dividend YieldN/A
Average Volume (3M)152.12K
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue Growth-100.00%
EPS Growth87.37%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.43
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside629.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.18
Revenue Forecast (FY)N/A
Adagio Medical Holdings Business Overview & Revenue Model
Company Description
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but n...
How the Company Makes Money
null...
Adagio Medical Holdings Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 269.00K | 300.00K | 189.00K | 270.00K |
| Gross Profit | -89.00K | -684.00K | -1.67M | -1.01M | -686.00K | -888.00K |
| EBITDA | -22.41M | -21.21M | -53.48M | -35.95M | -23.04M | -19.60M |
| Net Income | -27.14M | -25.08M | -53.76M | -38.15M | -23.67M | -19.94M |
Balance Sheet | ||||||
| Total Assets | 33.88M | 43.25M | 48.45M | 6.83M | 8.70M | 21.44M |
| Cash, Cash Equivalents and Short-Term Investments | 7.74M | 17.11M | 20.59M | 1.38M | 5.55M | 18.85M |
| Total Debt | 26.00M | 21.76M | 16.27M | 38.40M | 9.80M | 0.00 |
| Total Liabilities | 34.30M | 30.85M | 28.54M | 138.85M | 104.57M | 94.06M |
| Stockholders Equity | -415.00K | 12.40M | 19.91M | -132.02M | -95.88M | -72.62M |
Cash Flow | ||||||
| Free Cash Flow | -16.20M | -19.39M | -31.11M | -25.98M | -22.90M | -20.58M |
| Operating Cash Flow | -16.53M | -19.01M | -29.46M | -25.65M | -22.41M | -19.31M |
| Investing Cash Flow | -37.00K | -374.00K | -1.65M | -340.00K | -500.00K | -1.27M |
| Financing Cash Flow | 16.13M | 16.13M | 15.63M | 21.88M | 9.53M | 130.00K |
Adagio Medical Holdings Technical Analysis
Positive
0.48
Price Trends
0.63
Positive
0.88
Negative
0.93
Negative
Market Momentum
0.02
Negative
61.70
Neutral
46.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADGM, the sentiment is Positive. The current price of 0.48 is below the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.63, and below the 200-day MA of 0.93, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 61.70 is Neutral, neither overbought nor oversold. The STOCH value of 46.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADGM.
Adagio Medical Holdings Risk Analysis
Adagio Medical Holdings disclosed 78 risk factors in its most recent earnings report. Adagio Medical Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adagio Medical Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $15.18M | -0.54 | -382.50% | ― | -100.00% | 87.37% | |
46 Neutral | $33.93M | -0.13 | -49.65% | ― | -95.74% | -118.94% | |
45 Neutral | $4.50M | -0.14 | -2239.18% | ― | 33.77% | -20.22% | |
43 Neutral | $10.61M | -0.05 | -164.92% | ― | -9.46% | 18.03% | |
43 Neutral | $51.60M | -0.91 | 239.44% | ― | 10.38% | 20.70% |
* Healthcare Sector Average
ADGM
Adagio Medical Holdings
0.74
-0.61
-44.89%
CODX
Co-Diagnostics
1.50
-6.08
-80.20%
PAVM
PAVmed
4.75
-8.75
-64.81%
VVOS
Vivos Therapeutics
0.32
-4.26
-93.08%
COCH
Envoy Medical
0.71
-0.85
-54.66%
Adagio Medical Holdings Corporate Events
Executive/Board ChangesShareholder Meetings
Adagio Medical Shareholders Approve Directors and Auditor Ratification
Positive
Jun 16, 2026
On June 16, 2026, Adagio Medical Holdings, Inc. held its 2026 Annual Meeting of Stockholders, with 72.35% of outstanding shares present or represented by proxy. Stockholders elected Orly Mishan and Sean Salmon as directors to serve until the 2029 ...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Adagio Medical Faces Nasdaq Minimum Bid Price Noncompliance
Negative
Jun 12, 2026
On June 12, 2026, Adagio Medical Holdings, Inc. disclosed that it had received a notice from Nasdaq stating its common stock no longer met the exchange’s $1.00 minimum bid price requirement over the prior 30 consecutive business days, trigge...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Adagio Files PMA for Breakthrough Ventricular Ablation System
Positive
May 21, 2026
On May 21, 2026, Adagio Medical Holdings submitted a Premarket Approval application to the U.S. Food and Drug Administration for its vCLAS Ventricular Ablation System, designed to treat drug-refractory, recurrent, sustained monomorphic ventricular...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.